RT Journal Article
T1 SARS-CoV-2 Seroprevalence Studies in Pets, Spain
A1 Sánchez Morales, Lidia
A1 Barroso Arévalo, Sandra
A1 Barasona García-Arévalo, José Ángel
A1 Domínguez Rodríguez, Lucas José
A1 Sánchez-Vizcaíno Rodríguez, José Manuel
AB SARS-CoV-2 can infect domestic animals such as cats and dogs. The zoonotic origin of the disease requires surveillance on animals. Seroprevalence studies are useful tools for detecting previous exposure because the short period of virus shedding in animals makes detection of the virus difficult. We report on an extensive serosurvey on pets in Spain that covered 23 months. We included animals with exposure to SARS-CoV-2-infected persons, random animals, and stray animals in the study. We also evaluated epidemiologic variables such as human accumulated incidence and spatial location. We detected neutralizing antibodies in 3.59% of animals and showed a correlation between COVID-19 incidence in humans and positivity to antibody detection in pets. This study shows that more pets were infected with SARS-CoV-2 than in previous reports based on molecular research, and the findings highlight the need to establish preventive measures to avoid reverse zoonosis events.
SN 1080-6040
SN 1080-6059
YR 2023
FD 2023-06
LK https://hdl.handle.net/20.500.14352/107523
UL https://hdl.handle.net/20.500.14352/107523
LA eng
NO Barroso-Arévalo, S., Sánchez-Morales, L., Barasona, J. A., Domínguez, L., & Sánchez-Vizcaíno, J. M. (2023). SARS-CoV-2 Seroprevalence Studies in Pets, Spain. Emerging Infectious Diseases, 29(6), 1136-1142. https://doi.org/10.3201/eid2906.221737
NO Author contributions: conceptualization: S.B.-A., L.D., J.M.S.-V.; data curation: S.B.-A., L.S.-M., J.A.B.; formal analysis: S.B.-A., L.S.-M., J.A.B.; funding acquisition: J.M.S.-V., L.D.; laboratory analyses: S.B.-A., L.S.-M.; methodology: S.B.-A., L.S.-M., J.A.B., J.M.S.-V.; project administration: J.M.S.-V.; resources: L.D., J.M.S.-V.; software: S.B.-A., L.S.-M., J.A.B.; supervision: L.D., J.M.S.-V.; validation: S.B.-A., L.S.-M., J.A.B., J.M.S.-V.; visualization: S.B.-A., L.S.-M., J.A.B.; original draft preparation: S.B.-A., L.S.-M., J.A.B.; manuscript review and editing: S.B.-A., L.S.-M., J.A.B., L.D., J.M.S.-V.
NO Instituto de Salud Carlos III
NO European Union
NO Comunidad de Madrid
DS Docta Complutense
RD 22 abr 2025